BioStock: Evaxion Biotech shows strong clinical momentum in Q1

Q1 was a productive quarter for Danish immunotherapy company Evaxion Biotech, especially regarding the company’s clinical development.. Lead candidate EVX-01 received regulatory clearance in Australia for phase IIb initiation in melanoma patients, and patient recruitment was completed for the phase I/IIa clinical trial with EVX-02 in resectable melanoma. To cap the quarter off, Evaxion reported a strong cash position of 31.4 MUSD.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/05/evaxion-biotech-shows-strong-clinical-momentum-in-q1/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/